个人中心 - 老虎社区

LLQ123

IP属地：未知

帖子 · 4帖子 · 4
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- LLQ123LLQ123
  ·2021-06-29
  yes
  Tech stock rally sends S&P and Nasdaq to record highs
  - The Nasdaq and S&P 500 hit all-time highs on Monday, fueled by tech stocks as investors expect a robust earnings season while interest rates remain low.Big tech companies including Facebook Inc, Netflix Inc, Twitter Inc and Nvidia Corp were among the biggest boosts to the S&P 500 and the Nasdaq.The S&P 500 continued its recent momentum after paring some earlier losses, recording its third record high in a row, after logging its best weekly performance in 20 weeks last Friday.In contrast, cycl
  Tech stock rally sends S&P and Nasdaq to record highs
  35 2
  6
  分享
  举报
- LLQ123LLQ123
  ·2021-04-19
  good
  非常抱歉，此主贴已删除
  42 评论
  3
  分享
  举报
- LLQ123LLQ123
  ·2021-04-15
  oic
  'It was a wise decision to spread the risk': What Johnson & Johnson saga reveals about COVID-19 vaccination campaign
  "It's still a race between the variants and the vaccine," said Amesh Adalja, a senior scholar at the
  'It was a wise decision to spread the risk': What Johnson & Johnson saga reveals about COVID-19 vaccination campaign
  72 评论
  点赞
  分享
  举报
- LLQ123LLQ123
  ·2021-04-15
  oic
  非常抱歉，此主贴已删除
  148 评论
  点赞
  分享
  举报

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

老虎社区侵权投诉指引

中国互联网举报中心·北京互联网举报中心

网络谣言曝光台·扫黄打非举报中心

网络110报警服务

© 2018-2024 老虎社区版权所有

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

qrcode

关注我们

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":3581500004160787,"uuid":"3581500004160787","gmtCreate":1618406243219,"gmtModify":1618452631392,"name":"LLQ123","pinyin":"llq123","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/975309cd3a6c14b9b84d70a743d8eb57","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":14,"tweetSize":4,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":9,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"93.91%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.72%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":150454976,"gmtCreate":1624925645795,"gmtModify":1633946994502,"author":{"id":"3581500004160787","authorId":"3581500004160787","authorIdStr":"3581500004160787","name":"LLQ123","avatar":"https://static.tigerbbs.com/975309cd3a6c14b9b84d70a743d8eb57","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581500004160787"},"themes":[],"htmlText":"yes&nbsp;","listText":"yes&nbsp;","text":"yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/150454976","repostId":"2147837316","repostType":4,"repost":{"id":"2147837316","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1624921533,"share":"https://www.laohu8.com/m/news/2147837316?lang=&edition=full","pubTime":"2021-06-29 07:05","market":"us","language":"en","title":"Tech stock rally sends S&P and Nasdaq to record highs","url":"https://stock-news.laohu8.com/highlight/detail?id=2147837316","media":"Reuters","summary":" - The Nasdaq and S&P 500 hit all-time highs on Monday, fueled by tech stocks as investors expect a robust earnings season while interest rates remain low.Big tech companies including Facebook Inc, Netflix Inc, Twitter Inc and Nvidia Corp were among the biggest boosts to the S&P 500 and the Nasdaq.The S&P 500 continued its recent momentum after paring some earlier losses, recording its third record high in a row, after logging its best weekly performance in 20 weeks last Friday.In contrast, cycl","content":"<p>(Reuters) - The Nasdaq and S&amp;P 500 hit all-time highs on Monday, fueled by tech stocks as investors expect a robust earnings season while interest rates remain low.</p>\n<p>Big tech companies including Facebook Inc, Netflix Inc, Twitter Inc and Nvidia Corp were among the biggest boosts to the S&amp;P 500 and the Nasdaq.</p>\n<p>The S&amp;P 500 continued its recent momentum after paring some earlier losses, recording its third record high in a row, after logging its best weekly performance in 20 weeks last Friday.</p>\n<p>In contrast, cyclical sectors dropped sharply amid fears over a spike in COVID-19 cases across Asia. Financials and energy posted the biggest sectoral loss on S&amp;P 500, down by 0.81% and 3.33%, respectively.</p>\n<p>“It’s end of the quarter and investors may want to take some profits and rotate out of energy and stick with tech,” said Sam Stovall, chief investment strategist at CFRA Research in New York.</p>\n<p>Stovall expects stocks should continue their near-term climb as investors await the new earnings season, in which year-over-year earnings growth of S&amp;P 500 companies is expected to top 60%.</p>\n<p>The Dow Jones Industrial Average fell 150.57 points, or 0.44%, to close at 34,283.27. The S&amp;P 500 pared earlier losses and advanced from Friday’s record high by gaining 9.91 points, or 0.23%, to 4,290.61. The Nasdaq Composite added 140.12 points, or 0.98%, to 14,500.51.</p>\n<p>Both the S&amp;P 500 and the Nasdaq hit a series of record highs last week. the tech-heavy Nasdaq’s 5% gain in June is outpacing its peers as investors pile back in to tech-oriented growth stocks on diminishing worries about runaway inflation.</p>\n<p>“We believe with the Fed putting a realistic goal post, investors now have much more of a risk-on mentality going into the second half of the year. A lot of these tech names have underperformed, while fundamentals were very robust going into the June quarter,” said Wedbush Securities analyst Daniel Ives, who expects the Nasdaq to hit 16,000 by year-end.</p>\n<p>Facebook jumped over 4% as a U.S. judge granted the company’s motion to dismiss a Federal Trade Commission lawsuit. The social media giant finished Monday with over $1 trillion in market capitalization.</p>\n<p>On the Nasdaq 100, the largest gainer was Nvidia Corp, which rose 5.0% after major chip makers Broadcom Inc, Marvell and Taiwan-based MediaTek endorsed its $40 billion deal to buy UK chip designer Arm.</p>\n<p>With the S&amp;P 500 up almost 14% as the first half of 2021 draws to a close, activity in some areas of the market indicates concern over potential volatility, with some investors suggesting the market may be overdue for a significant pullback.</p>\n<p>On the economic front, investor attention will be focused on consumer confidence data, a private jobs report and a crucial monthly employment report due later this week. Quarterly results from Micron Technology Inc and Walgreens Boots Alliance are also slated for this week.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.38-to-1 ratio; on Nasdaq, a 1.09-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 36 new 52-week highs and no new lows; the Nasdaq Composite recorded 100 new highs and 31 new lows.</p>\n<p>Volume on U.S. exchanges was 9.55 billion shares, compared with the 11.17 billion average for the full session over the last 20 trading days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tech stock rally sends S&P and Nasdaq to record highs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTech stock rally sends S&P and Nasdaq to record highs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-29 07:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Reuters) - The Nasdaq and S&amp;P 500 hit all-time highs on Monday, fueled by tech stocks as investors expect a robust earnings season while interest rates remain low.</p>\n<p>Big tech companies including Facebook Inc, Netflix Inc, Twitter Inc and Nvidia Corp were among the biggest boosts to the S&amp;P 500 and the Nasdaq.</p>\n<p>The S&amp;P 500 continued its recent momentum after paring some earlier losses, recording its third record high in a row, after logging its best weekly performance in 20 weeks last Friday.</p>\n<p>In contrast, cyclical sectors dropped sharply amid fears over a spike in COVID-19 cases across Asia. Financials and energy posted the biggest sectoral loss on S&amp;P 500, down by 0.81% and 3.33%, respectively.</p>\n<p>“It’s end of the quarter and investors may want to take some profits and rotate out of energy and stick with tech,” said Sam Stovall, chief investment strategist at CFRA Research in New York.</p>\n<p>Stovall expects stocks should continue their near-term climb as investors await the new earnings season, in which year-over-year earnings growth of S&amp;P 500 companies is expected to top 60%.</p>\n<p>The Dow Jones Industrial Average fell 150.57 points, or 0.44%, to close at 34,283.27. The S&amp;P 500 pared earlier losses and advanced from Friday’s record high by gaining 9.91 points, or 0.23%, to 4,290.61. The Nasdaq Composite added 140.12 points, or 0.98%, to 14,500.51.</p>\n<p>Both the S&amp;P 500 and the Nasdaq hit a series of record highs last week. the tech-heavy Nasdaq’s 5% gain in June is outpacing its peers as investors pile back in to tech-oriented growth stocks on diminishing worries about runaway inflation.</p>\n<p>“We believe with the Fed putting a realistic goal post, investors now have much more of a risk-on mentality going into the second half of the year. A lot of these tech names have underperformed, while fundamentals were very robust going into the June quarter,” said Wedbush Securities analyst Daniel Ives, who expects the Nasdaq to hit 16,000 by year-end.</p>\n<p>Facebook jumped over 4% as a U.S. judge granted the company’s motion to dismiss a Federal Trade Commission lawsuit. The social media giant finished Monday with over $1 trillion in market capitalization.</p>\n<p>On the Nasdaq 100, the largest gainer was Nvidia Corp, which rose 5.0% after major chip makers Broadcom Inc, Marvell and Taiwan-based MediaTek endorsed its $40 billion deal to buy UK chip designer Arm.</p>\n<p>With the S&amp;P 500 up almost 14% as the first half of 2021 draws to a close, activity in some areas of the market indicates concern over potential volatility, with some investors suggesting the market may be overdue for a significant pullback.</p>\n<p>On the economic front, investor attention will be focused on consumer confidence data, a private jobs report and a crucial monthly employment report due later this week. Quarterly results from Micron Technology Inc and Walgreens Boots Alliance are also slated for this week.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.38-to-1 ratio; on Nasdaq, a 1.09-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 36 new 52-week highs and no new lows; the Nasdaq Composite recorded 100 new highs and 31 new lows.</p>\n<p>Volume on U.S. exchanges was 9.55 billion shares, compared with the 11.17 billion average for the full session over the last 20 trading days.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"QLD":"纳指两倍做多ETF",".IXIC":"NASDAQ Composite","NVDA":"英伟达","QID":"纳指两倍做空ETF","MU":"美光科技","SQQQ":"纳指三倍做空ETF",".SPX":"S&P 500 Index","TQQQ":"纳指三倍做多ETF","PSQ":"纳指反向ETF","TWTR":"Twitter","NFLX":"奈飞","QQQ":"纳指100ETF","NDAQ":"纳斯达克OMX交易所",".DJI":"道琼斯","WBA":"沃尔格林联合博姿"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2147837316","content_text":"(Reuters) - The Nasdaq and S&P 500 hit all-time highs on Monday, fueled by tech stocks as investors expect a robust earnings season while interest rates remain low.\nBig tech companies including Facebook Inc, Netflix Inc, Twitter Inc and Nvidia Corp were among the biggest boosts to the S&P 500 and the Nasdaq.\nThe S&P 500 continued its recent momentum after paring some earlier losses, recording its third record high in a row, after logging its best weekly performance in 20 weeks last Friday.\nIn contrast, cyclical sectors dropped sharply amid fears over a spike in COVID-19 cases across Asia. Financials and energy posted the biggest sectoral loss on S&P 500, down by 0.81% and 3.33%, respectively.\n“It’s end of the quarter and investors may want to take some profits and rotate out of energy and stick with tech,” said Sam Stovall, chief investment strategist at CFRA Research in New York.\nStovall expects stocks should continue their near-term climb as investors await the new earnings season, in which year-over-year earnings growth of S&P 500 companies is expected to top 60%.\nThe Dow Jones Industrial Average fell 150.57 points, or 0.44%, to close at 34,283.27. The S&P 500 pared earlier losses and advanced from Friday’s record high by gaining 9.91 points, or 0.23%, to 4,290.61. The Nasdaq Composite added 140.12 points, or 0.98%, to 14,500.51.\nBoth the S&P 500 and the Nasdaq hit a series of record highs last week. the tech-heavy Nasdaq’s 5% gain in June is outpacing its peers as investors pile back in to tech-oriented growth stocks on diminishing worries about runaway inflation.\n“We believe with the Fed putting a realistic goal post, investors now have much more of a risk-on mentality going into the second half of the year. A lot of these tech names have underperformed, while fundamentals were very robust going into the June quarter,” said Wedbush Securities analyst Daniel Ives, who expects the Nasdaq to hit 16,000 by year-end.\nFacebook jumped over 4% as a U.S. judge granted the company’s motion to dismiss a Federal Trade Commission lawsuit. The social media giant finished Monday with over $1 trillion in market capitalization.\nOn the Nasdaq 100, the largest gainer was Nvidia Corp, which rose 5.0% after major chip makers Broadcom Inc, Marvell and Taiwan-based MediaTek endorsed its $40 billion deal to buy UK chip designer Arm.\nWith the S&P 500 up almost 14% as the first half of 2021 draws to a close, activity in some areas of the market indicates concern over potential volatility, with some investors suggesting the market may be overdue for a significant pullback.\nOn the economic front, investor attention will be focused on consumer confidence data, a private jobs report and a crucial monthly employment report due later this week. Quarterly results from Micron Technology Inc and Walgreens Boots Alliance are also slated for this week.\nDeclining issues outnumbered advancing ones on the NYSE by a 1.38-to-1 ratio; on Nasdaq, a 1.09-to-1 ratio favored decliners.\nThe S&P 500 posted 36 new 52-week highs and no new lows; the Nasdaq Composite recorded 100 new highs and 31 new lows.\nVolume on U.S. exchanges was 9.55 billion shares, compared with the 11.17 billion average for the full session over the last 20 trading days.","news_type":1},"isVote":1,"tweetType":1,"viewCount":35,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":373351288,"gmtCreate":1618824285344,"gmtModify":1634290666820,"author":{"id":"3581500004160787","authorId":"3581500004160787","authorIdStr":"3581500004160787","name":"LLQ123","avatar":"https://static.tigerbbs.com/975309cd3a6c14b9b84d70a743d8eb57","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581500004160787"},"themes":[],"htmlText":"good&nbsp;","listText":"good&nbsp;","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/373351288","repostId":"2128525488","repostType":4,"isVote":1,"tweetType":1,"viewCount":42,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":344409124,"gmtCreate":1618420833568,"gmtModify":1634293041408,"author":{"id":"3581500004160787","authorId":"3581500004160787","authorIdStr":"3581500004160787","name":"LLQ123","avatar":"https://static.tigerbbs.com/975309cd3a6c14b9b84d70a743d8eb57","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581500004160787"},"themes":[],"htmlText":"oic&nbsp;","listText":"oic&nbsp;","text":"oic","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/344409124","repostId":"2127078424","repostType":4,"repost":{"id":"2127078424","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1618412040,"share":"https://www.laohu8.com/m/news/2127078424?lang=&edition=full","pubTime":"2021-04-14 22:54","market":"us","language":"en","title":"'It was a wise decision to spread the risk': What Johnson & Johnson saga reveals about COVID-19 vaccination campaign","url":"https://stock-news.laohu8.com/highlight/detail?id=2127078424","media":"Dow Jones","summary":"\"It's still a race between the variants and the vaccine,\" said Amesh Adalja, a senior scholar at the","content":"<p>\"It's still a race between the variants and the vaccine,\" said Amesh Adalja, a senior scholar at the John Hopkins Center for Health Security</p><p>The United States strategy to reach herd immunity through mass vaccination involves a delicate -- sometimes tricky -- dance with side effects, public opinion and virus variants.</p><p>All three are unpredictable, and can turn when you least expect it.</p><p>The rollout of coronavirus vaccines has not been without challenges, but the Biden administration's strategy of not relying on just <a href=\"https://laohu8.com/S/AONE\">one</a> vaccine has limited the scope of a setback involving any <a href=\"https://laohu8.com/S/AONE.U\">one</a> product. As this week's events illustrate, however, the suspension of a vaccine run the risk of affecting public opinion surrounding the entire process.</p><p>The Food and Drug Administration and the Centers for Disease Control and Prevention recommended a pause  in the use of the Johnson &amp; Johnson vaccine on Tuesday as they examine six severe cases of blood clots among the roughly 7 million people who have had the vaccine administered. J&amp;J also halted its rollout in Europe.</p><p>The vaccine from J&amp;J unit <a href=\"https://laohu8.com/S/JNJ\">$(JNJ)$</a> Janssen is an adenovirus vector-based vaccine that only requires one shot. Clinical trials showed it had 72% efficacy in the U.S .</p><p>The two-shot mRNA-based vaccines made by Pfizer <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> with German partner <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) and Moderna <a href=\"https://laohu8.com/S/MRNA\">$(MRNA)$</a> make up the majority of shots administered in the U.S., and bith were about 95% effective in clinical trials. (Mayo Clinic research puts their \"real world</p><p>Currently, 22.7%  to discuss the cases, and the FDA has opened an investigation into the cause of the clots.</p><p>The J&amp;J blood-clot issue is similar to one that caused many European countries to pause and/or restrict use of the AstraZeneca (AZN.LN) vaccine developed with Oxford University, which is also an adenovirus viral vector-based vaccine. The U.K. has restricted its use to those over age 30.</p><p>On Wednesday, Denmark said it would halt use of AstraZeneca. \"The Danish Health Authority has decided to continue the vaccination against COVID-19 without the vaccine from AstraZeneca,\" it said in a statement. Other European countries have restricted its use.</p><p>\"It's still a race between the variants  and the vaccine,\" Amesh Adalja, a senior scholar at the John Hopkins Center for Health Security and a spokesman for the Infectious Diseases Society of America, told MarketWatch.</p><p>Operation Warp Speed, as Trump administration called its vaccine development and distribution program, has been key to this success, he said. \"Part of Operation Warp Speed was not knowing which ones would cross the finish line, and having alternative vaccines that can handle the J&amp;J pause and other vaccines in the pipeline,\" Adalja said. \"We are increasingly not supply-constrained in the U.S. because of the bulk manufacture of vaccines.\"</p><p>The FDA and CDC said the J&amp;J pause would give their scientists time to investigate the six cases of blood clotting in vaccinated individuals. Those cases of cerebral venous sinus thrombosis, a blood-clotting disorder, have emerged out of the 6.8 million--plus people in the U.S. who have received this vaccine.</p><p>All six cases of blood clots occurred in women ages 18 to 48. One woman died, and a second remains in critical condition, according to information released by the FDA. \"We are recommending a pause in the use of this vaccine out of an abundance of caution,\" health officials said .</p><p>\"Hiccups in production and hiccups in safety are inevitable,\" said Dr. Andrew Pavia, the George and Esther Gross Presidential Professor at the University of Utah and head of the Division of Pediatric Infectious Diseases. \"It was a wise decision to spread the risk,\" he told MarketWatch. \"Factories can be hit by a hurricane, run out of a supply, or be hit by contamination that forces them to shut down.\"</p><p>President Joe Biden, speaking to the media during an Oval Office meeting on Tuesday, emphasized that his administration has ordered 600 million doses of the mRNA vaccines from Pfizer and Moderna and thus can vaccinate all adults even without either the Johnson &amp; Johnson vaccine or AstraZeneca's, which has not been authorized in the U.S. and has been paused in other countries, also over blood-clot concerns.</p><p>But the different efficacies of vaccines, their reported responses to variants and their respective side effects appear to take tolls on public opinion. \"When I was offered Moderna, J&amp;J wasn't even an option. It was never in my consideration not to take it,\" said Maury Newburger, a New York travel consultant who received the Moderna vaccine in March.</p><p>\"Knowing what I know now, I probably would not take the J&amp;J,\" he said. \"I still think I would have taken the two-shot vaccines.\"</p><p><b>The good (and the bad) news</b></p><p>The good news: Pfizer-BioNTech and Moderna supply the majority of vaccines in the U.S., and currently ship roughly 23 million doses a week in the country. The White House said the J&amp;J pause would not have a \"significant impact\" on the rollout in the U.S.</p><p>\"We've been doing fairly well and not having the outcome Europe is having,\" Adalja said. \"We have successfully vaccinated high-risk populations: nursing-home residents and those in community dwellings. We're nowhere near the winter surge. Nursing-home deaths have plummeted.\"</p><p>White House COVID-19 response coordinator Jeff Zients said in a statement : \"This [J&amp;J pause] announcement will not have a significant impact on our vaccination plan: [the] Johnson &amp; Johnson vaccine makes up less than 5% of the recorded shots in arms in the United States to date.\"</p><p>The latest complication has further delayed a rocky rollout in the European Union, which ordered approximately 200 million doses of the J&amp;J vaccine in 2021.</p><p>On Wednesday, the EU ordered 50 million more COVID-19 vaccine doses from Pfizer-BioNTech. \"Those 50 million doses were initially foreseen for delivery in the fourth quarter of 2021. Now they are available in quarter 2,\" European Commission President Ursula von der Leyen said in a statement .</p><p>\"We have made the decision to proactively delay the rollout of our vaccine in Europe,\" J&amp;J said in a statement  Tuesday. The U.K. has ordered 30 million doses of the J&amp;J vaccine, although it has not yet been authorized for use there.</p><p>Now, for the bad news: \"Unfortunately, there is always going to be a halo effect in a negative way,\" Dr. Aaron Glatt, who chairs the department of medicine at Mount Sinai South Nassau in Oceanside, N.Y., told MarketWatch. \"What's happened with J&amp;J is forcing people to have questions with all vaccines.\"</p><p>The J&amp;J vaccine \"remains an extremely important vaccine for a fatal disease,\" he added. \"These types of things make vaccine-hesitant people more concerned.\"</p><p>\"Certainly, having other vaccines has been extremely helpful because there can always be manufacturing issues, or different strains may or may not be effective against a particular vaccine.  That's not intentional, it's just the way science works,\" Glatt said.</p><p>\"The boosters, if and when they do come, will be more easily approved,\" he added. \"We've done most of the legwork already. It's impossible to predict what will happen. It's possible the vaccines will have efficacy against different strains. Time will tell, and the different strains will tell as well.\"</p><p>In one recent Kaiser Family Foundation poll , taken before the J&amp;J vaccination pause, 13% of Americans said they would definitely not get a vaccine, and 7% said they would get one only if required.</p><p>\"As humans, we are not very good at translating risk into action,\" Pavia said. \"If I have the chance of being one of the 500,000 who die of COVID, how do I balance that with the one person who had a fatal side effect, if it's a side effect at all? It's the same perceptual problem when we blindly drive to the airport texting, yet we worry about the airplane.\"</p><p>In the aftermath of the J&amp;J vaccine pause, Barbara Alexander, president of the Infectious Diseases Society of America, said that the American public must continue to receive clear, accurate and up-to-date information, and have its questions answered, \"so that we can maintain and build trust and confidence in COVID-19 vaccines.\"</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>'It was a wise decision to spread the risk': What Johnson & Johnson saga reveals about COVID-19 vaccination campaign</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n'It was a wise decision to spread the risk': What Johnson & Johnson saga reveals about COVID-19 vaccination campaign\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-04-14 22:54</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>\"It's still a race between the variants and the vaccine,\" said Amesh Adalja, a senior scholar at the John Hopkins Center for Health Security</p><p>The United States strategy to reach herd immunity through mass vaccination involves a delicate -- sometimes tricky -- dance with side effects, public opinion and virus variants.</p><p>All three are unpredictable, and can turn when you least expect it.</p><p>The rollout of coronavirus vaccines has not been without challenges, but the Biden administration's strategy of not relying on just <a href=\"https://laohu8.com/S/AONE\">one</a> vaccine has limited the scope of a setback involving any <a href=\"https://laohu8.com/S/AONE.U\">one</a> product. As this week's events illustrate, however, the suspension of a vaccine run the risk of affecting public opinion surrounding the entire process.</p><p>The Food and Drug Administration and the Centers for Disease Control and Prevention recommended a pause  in the use of the Johnson &amp; Johnson vaccine on Tuesday as they examine six severe cases of blood clots among the roughly 7 million people who have had the vaccine administered. J&amp;J also halted its rollout in Europe.</p><p>The vaccine from J&amp;J unit <a href=\"https://laohu8.com/S/JNJ\">$(JNJ)$</a> Janssen is an adenovirus vector-based vaccine that only requires one shot. Clinical trials showed it had 72% efficacy in the U.S .</p><p>The two-shot mRNA-based vaccines made by Pfizer <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> with German partner <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) and Moderna <a href=\"https://laohu8.com/S/MRNA\">$(MRNA)$</a> make up the majority of shots administered in the U.S., and bith were about 95% effective in clinical trials. (Mayo Clinic research puts their \"real world</p><p>Currently, 22.7%  to discuss the cases, and the FDA has opened an investigation into the cause of the clots.</p><p>The J&amp;J blood-clot issue is similar to one that caused many European countries to pause and/or restrict use of the AstraZeneca (AZN.LN) vaccine developed with Oxford University, which is also an adenovirus viral vector-based vaccine. The U.K. has restricted its use to those over age 30.</p><p>On Wednesday, Denmark said it would halt use of AstraZeneca. \"The Danish Health Authority has decided to continue the vaccination against COVID-19 without the vaccine from AstraZeneca,\" it said in a statement. Other European countries have restricted its use.</p><p>\"It's still a race between the variants  and the vaccine,\" Amesh Adalja, a senior scholar at the John Hopkins Center for Health Security and a spokesman for the Infectious Diseases Society of America, told MarketWatch.</p><p>Operation Warp Speed, as Trump administration called its vaccine development and distribution program, has been key to this success, he said. \"Part of Operation Warp Speed was not knowing which ones would cross the finish line, and having alternative vaccines that can handle the J&amp;J pause and other vaccines in the pipeline,\" Adalja said. \"We are increasingly not supply-constrained in the U.S. because of the bulk manufacture of vaccines.\"</p><p>The FDA and CDC said the J&amp;J pause would give their scientists time to investigate the six cases of blood clotting in vaccinated individuals. Those cases of cerebral venous sinus thrombosis, a blood-clotting disorder, have emerged out of the 6.8 million--plus people in the U.S. who have received this vaccine.</p><p>All six cases of blood clots occurred in women ages 18 to 48. One woman died, and a second remains in critical condition, according to information released by the FDA. \"We are recommending a pause in the use of this vaccine out of an abundance of caution,\" health officials said .</p><p>\"Hiccups in production and hiccups in safety are inevitable,\" said Dr. Andrew Pavia, the George and Esther Gross Presidential Professor at the University of Utah and head of the Division of Pediatric Infectious Diseases. \"It was a wise decision to spread the risk,\" he told MarketWatch. \"Factories can be hit by a hurricane, run out of a supply, or be hit by contamination that forces them to shut down.\"</p><p>President Joe Biden, speaking to the media during an Oval Office meeting on Tuesday, emphasized that his administration has ordered 600 million doses of the mRNA vaccines from Pfizer and Moderna and thus can vaccinate all adults even without either the Johnson &amp; Johnson vaccine or AstraZeneca's, which has not been authorized in the U.S. and has been paused in other countries, also over blood-clot concerns.</p><p>But the different efficacies of vaccines, their reported responses to variants and their respective side effects appear to take tolls on public opinion. \"When I was offered Moderna, J&amp;J wasn't even an option. It was never in my consideration not to take it,\" said Maury Newburger, a New York travel consultant who received the Moderna vaccine in March.</p><p>\"Knowing what I know now, I probably would not take the J&amp;J,\" he said. \"I still think I would have taken the two-shot vaccines.\"</p><p><b>The good (and the bad) news</b></p><p>The good news: Pfizer-BioNTech and Moderna supply the majority of vaccines in the U.S., and currently ship roughly 23 million doses a week in the country. The White House said the J&amp;J pause would not have a \"significant impact\" on the rollout in the U.S.</p><p>\"We've been doing fairly well and not having the outcome Europe is having,\" Adalja said. \"We have successfully vaccinated high-risk populations: nursing-home residents and those in community dwellings. We're nowhere near the winter surge. Nursing-home deaths have plummeted.\"</p><p>White House COVID-19 response coordinator Jeff Zients said in a statement : \"This [J&amp;J pause] announcement will not have a significant impact on our vaccination plan: [the] Johnson &amp; Johnson vaccine makes up less than 5% of the recorded shots in arms in the United States to date.\"</p><p>The latest complication has further delayed a rocky rollout in the European Union, which ordered approximately 200 million doses of the J&amp;J vaccine in 2021.</p><p>On Wednesday, the EU ordered 50 million more COVID-19 vaccine doses from Pfizer-BioNTech. \"Those 50 million doses were initially foreseen for delivery in the fourth quarter of 2021. Now they are available in quarter 2,\" European Commission President Ursula von der Leyen said in a statement .</p><p>\"We have made the decision to proactively delay the rollout of our vaccine in Europe,\" J&amp;J said in a statement  Tuesday. The U.K. has ordered 30 million doses of the J&amp;J vaccine, although it has not yet been authorized for use there.</p><p>Now, for the bad news: \"Unfortunately, there is always going to be a halo effect in a negative way,\" Dr. Aaron Glatt, who chairs the department of medicine at Mount Sinai South Nassau in Oceanside, N.Y., told MarketWatch. \"What's happened with J&amp;J is forcing people to have questions with all vaccines.\"</p><p>The J&amp;J vaccine \"remains an extremely important vaccine for a fatal disease,\" he added. \"These types of things make vaccine-hesitant people more concerned.\"</p><p>\"Certainly, having other vaccines has been extremely helpful because there can always be manufacturing issues, or different strains may or may not be effective against a particular vaccine.  That's not intentional, it's just the way science works,\" Glatt said.</p><p>\"The boosters, if and when they do come, will be more easily approved,\" he added. \"We've done most of the legwork already. It's impossible to predict what will happen. It's possible the vaccines will have efficacy against different strains. Time will tell, and the different strains will tell as well.\"</p><p>In one recent Kaiser Family Foundation poll , taken before the J&amp;J vaccination pause, 13% of Americans said they would definitely not get a vaccine, and 7% said they would get one only if required.</p><p>\"As humans, we are not very good at translating risk into action,\" Pavia said. \"If I have the chance of being one of the 500,000 who die of COVID, how do I balance that with the one person who had a fatal side effect, if it's a side effect at all? It's the same perceptual problem when we blindly drive to the airport texting, yet we worry about the airplane.\"</p><p>In the aftermath of the J&amp;J vaccine pause, Barbara Alexander, president of the Infectious Diseases Society of America, said that the American public must continue to receive clear, accurate and up-to-date information, and have its questions answered, \"so that we can maintain and build trust and confidence in COVID-19 vaccines.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127078424","content_text":"\"It's still a race between the variants and the vaccine,\" said Amesh Adalja, a senior scholar at the John Hopkins Center for Health SecurityThe United States strategy to reach herd immunity through mass vaccination involves a delicate -- sometimes tricky -- dance with side effects, public opinion and virus variants.All three are unpredictable, and can turn when you least expect it.The rollout of coronavirus vaccines has not been without challenges, but the Biden administration's strategy of not relying on just one vaccine has limited the scope of a setback involving any one product. As this week's events illustrate, however, the suspension of a vaccine run the risk of affecting public opinion surrounding the entire process.The Food and Drug Administration and the Centers for Disease Control and Prevention recommended a pause  in the use of the Johnson & Johnson vaccine on Tuesday as they examine six severe cases of blood clots among the roughly 7 million people who have had the vaccine administered. J&J also halted its rollout in Europe.The vaccine from J&J unit $(JNJ)$ Janssen is an adenovirus vector-based vaccine that only requires one shot. Clinical trials showed it had 72% efficacy in the U.S .The two-shot mRNA-based vaccines made by Pfizer $(PFE)$ with German partner BioNTech SE (BNTX) and Moderna $(MRNA)$ make up the majority of shots administered in the U.S., and bith were about 95% effective in clinical trials. (Mayo Clinic research puts their \"real worldCurrently, 22.7%  to discuss the cases, and the FDA has opened an investigation into the cause of the clots.The J&J blood-clot issue is similar to one that caused many European countries to pause and/or restrict use of the AstraZeneca (AZN.LN) vaccine developed with Oxford University, which is also an adenovirus viral vector-based vaccine. The U.K. has restricted its use to those over age 30.On Wednesday, Denmark said it would halt use of AstraZeneca. \"The Danish Health Authority has decided to continue the vaccination against COVID-19 without the vaccine from AstraZeneca,\" it said in a statement. Other European countries have restricted its use.\"It's still a race between the variants  and the vaccine,\" Amesh Adalja, a senior scholar at the John Hopkins Center for Health Security and a spokesman for the Infectious Diseases Society of America, told MarketWatch.Operation Warp Speed, as Trump administration called its vaccine development and distribution program, has been key to this success, he said. \"Part of Operation Warp Speed was not knowing which ones would cross the finish line, and having alternative vaccines that can handle the J&J pause and other vaccines in the pipeline,\" Adalja said. \"We are increasingly not supply-constrained in the U.S. because of the bulk manufacture of vaccines.\"The FDA and CDC said the J&J pause would give their scientists time to investigate the six cases of blood clotting in vaccinated individuals. Those cases of cerebral venous sinus thrombosis, a blood-clotting disorder, have emerged out of the 6.8 million--plus people in the U.S. who have received this vaccine.All six cases of blood clots occurred in women ages 18 to 48. One woman died, and a second remains in critical condition, according to information released by the FDA. \"We are recommending a pause in the use of this vaccine out of an abundance of caution,\" health officials said .\"Hiccups in production and hiccups in safety are inevitable,\" said Dr. Andrew Pavia, the George and Esther Gross Presidential Professor at the University of Utah and head of the Division of Pediatric Infectious Diseases. \"It was a wise decision to spread the risk,\" he told MarketWatch. \"Factories can be hit by a hurricane, run out of a supply, or be hit by contamination that forces them to shut down.\"President Joe Biden, speaking to the media during an Oval Office meeting on Tuesday, emphasized that his administration has ordered 600 million doses of the mRNA vaccines from Pfizer and Moderna and thus can vaccinate all adults even without either the Johnson & Johnson vaccine or AstraZeneca's, which has not been authorized in the U.S. and has been paused in other countries, also over blood-clot concerns.But the different efficacies of vaccines, their reported responses to variants and their respective side effects appear to take tolls on public opinion. \"When I was offered Moderna, J&J wasn't even an option. It was never in my consideration not to take it,\" said Maury Newburger, a New York travel consultant who received the Moderna vaccine in March.\"Knowing what I know now, I probably would not take the J&J,\" he said. \"I still think I would have taken the two-shot vaccines.\"The good (and the bad) newsThe good news: Pfizer-BioNTech and Moderna supply the majority of vaccines in the U.S., and currently ship roughly 23 million doses a week in the country. The White House said the J&J pause would not have a \"significant impact\" on the rollout in the U.S.\"We've been doing fairly well and not having the outcome Europe is having,\" Adalja said. \"We have successfully vaccinated high-risk populations: nursing-home residents and those in community dwellings. We're nowhere near the winter surge. Nursing-home deaths have plummeted.\"White House COVID-19 response coordinator Jeff Zients said in a statement : \"This [J&J pause] announcement will not have a significant impact on our vaccination plan: [the] Johnson & Johnson vaccine makes up less than 5% of the recorded shots in arms in the United States to date.\"The latest complication has further delayed a rocky rollout in the European Union, which ordered approximately 200 million doses of the J&J vaccine in 2021.On Wednesday, the EU ordered 50 million more COVID-19 vaccine doses from Pfizer-BioNTech. \"Those 50 million doses were initially foreseen for delivery in the fourth quarter of 2021. Now they are available in quarter 2,\" European Commission President Ursula von der Leyen said in a statement .\"We have made the decision to proactively delay the rollout of our vaccine in Europe,\" J&J said in a statement  Tuesday. The U.K. has ordered 30 million doses of the J&J vaccine, although it has not yet been authorized for use there.Now, for the bad news: \"Unfortunately, there is always going to be a halo effect in a negative way,\" Dr. Aaron Glatt, who chairs the department of medicine at Mount Sinai South Nassau in Oceanside, N.Y., told MarketWatch. \"What's happened with J&J is forcing people to have questions with all vaccines.\"The J&J vaccine \"remains an extremely important vaccine for a fatal disease,\" he added. \"These types of things make vaccine-hesitant people more concerned.\"\"Certainly, having other vaccines has been extremely helpful because there can always be manufacturing issues, or different strains may or may not be effective against a particular vaccine.  That's not intentional, it's just the way science works,\" Glatt said.\"The boosters, if and when they do come, will be more easily approved,\" he added. \"We've done most of the legwork already. It's impossible to predict what will happen. It's possible the vaccines will have efficacy against different strains. Time will tell, and the different strains will tell as well.\"In one recent Kaiser Family Foundation poll , taken before the J&J vaccination pause, 13% of Americans said they would definitely not get a vaccine, and 7% said they would get one only if required.\"As humans, we are not very good at translating risk into action,\" Pavia said. \"If I have the chance of being one of the 500,000 who die of COVID, how do I balance that with the one person who had a fatal side effect, if it's a side effect at all? It's the same perceptual problem when we blindly drive to the airport texting, yet we worry about the airplane.\"In the aftermath of the J&J vaccine pause, Barbara Alexander, president of the Infectious Diseases Society of America, said that the American public must continue to receive clear, accurate and up-to-date information, and have its questions answered, \"so that we can maintain and build trust and confidence in COVID-19 vaccines.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":72,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":344577345,"gmtCreate":1618420634887,"gmtModify":1634293042827,"author":{"id":"3581500004160787","authorId":"3581500004160787","authorIdStr":"3581500004160787","name":"LLQ123","avatar":"https://static.tigerbbs.com/975309cd3a6c14b9b84d70a743d8eb57","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581500004160787"},"themes":[],"htmlText":"oic&nbsp;","listText":"oic&nbsp;","text":"oic","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/344577345","repostId":"2127078424","repostType":4,"isVote":1,"tweetType":1,"viewCount":148,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}